Letter: Tralokinumab Dose Spacing in Moderate-to-Severe Atopic Dermatitis: A Real-World Case Series

Abstract

Get full access to this article

View all access options for this article.

References

Wollenberg

, Blauvelt

, Guttman-Yassky

, et al.; ECZTRA 1 and ECZTRA 2 study investigators. Tralokinumab for moderate-to-severe atopic dermatitis: Results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021; 184(3):437–449; doi: 10.1111/bjd.19574

Simpson

, Pink

, Blauvelt

, et al. Tralokinumab efficacy over 1 year in adults with moderate-to-severe atopic dermatitis: Pooled data from two phase III trials. Am J Clin Dermatol. 2023; 24(6):939–952; doi: 10.1007/s40257-023-00806-3

Barei

, Calzari

, Pezzolo

, et al. Efficacy and drug survival of tralokinumab in patients with severe atopic dermatitis: An 18-month multicentre study. Clin Exp Dermatol. 2025; 50(7):1373–1384; doi: 10.1093/ced/llaf062

Weidinger

, Bewley

, Hong

, et al. Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis. Br J Dermatol. 2025; 192(3):410–419; doi: 10.1093/bjd/ljae439

Mastorino

, Borrelli

, Macagno

, et al. Therapeutic modulation of dupilumab in patients with severe atopic dermatitis: Clinical effectiveness in real life. Dermatitis. 2024; 35(6):625–635; doi: 10.1089/derm.2024.0146